MX2015012043A - Agonistas muscarinicos. - Google Patents
Agonistas muscarinicos.Info
- Publication number
- MX2015012043A MX2015012043A MX2015012043A MX2015012043A MX2015012043A MX 2015012043 A MX2015012043 A MX 2015012043A MX 2015012043 A MX2015012043 A MX 2015012043A MX 2015012043 A MX2015012043 A MX 2015012043A MX 2015012043 A MX2015012043 A MX 2015012043A
- Authority
- MX
- Mexico
- Prior art keywords
- muscarinic agonists
- cholinergic
- disease
- compounds
- modification
- Prior art date
Links
- 239000000472 muscarinic agonist Substances 0.000 title 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790364P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/026998 WO2014152144A1 (en) | 2013-03-15 | 2014-03-14 | Muscarinic agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012043A true MX2015012043A (es) | 2016-03-17 |
Family
ID=50439523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012043A MX2015012043A (es) | 2013-03-15 | 2014-03-14 | Agonistas muscarinicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9670209B2 (enExample) |
| EP (1) | EP2976079A1 (enExample) |
| JP (1) | JP2016513677A (enExample) |
| KR (1) | KR20150143439A (enExample) |
| CN (1) | CN105120865A (enExample) |
| AU (1) | AU2014240139A1 (enExample) |
| BR (1) | BR112015021271A2 (enExample) |
| CA (1) | CA2903276A1 (enExample) |
| IL (1) | IL241001A0 (enExample) |
| MX (1) | MX2015012043A (enExample) |
| RU (1) | RU2015144155A (enExample) |
| TW (1) | TW201446761A (enExample) |
| WO (1) | WO2014152144A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015144155A (ru) | 2013-03-15 | 2017-04-24 | Акадиа Фармасьютикалз Инк. | Мускариновые агонисты |
| KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| EP3436434B1 (en) | 2016-03-31 | 2020-07-08 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707798A (en) | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
| JPH10152470A (ja) * | 1996-09-25 | 1998-06-09 | Yoshitomi Pharmaceut Ind Ltd | ピペラジン化合物 |
| EP1535912A1 (en) | 2000-04-28 | 2005-06-01 | Arcadia Pharmaceuticals Inc. | Muscarinic agonists |
| ES2238437T3 (es) | 2000-04-28 | 2005-09-01 | Acadia Pharmaceuticals Inc. | Agonistas muscarinicos. |
| US7550459B2 (en) * | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| CA2520125A1 (en) * | 2003-03-28 | 2004-10-14 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| RU2015144155A (ru) | 2013-03-15 | 2017-04-24 | Акадиа Фармасьютикалз Инк. | Мускариновые агонисты |
-
2014
- 2014-03-14 RU RU2015144155A patent/RU2015144155A/ru not_active Application Discontinuation
- 2014-03-14 AU AU2014240139A patent/AU2014240139A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/026998 patent/WO2014152144A1/en not_active Ceased
- 2014-03-14 JP JP2016502306A patent/JP2016513677A/ja active Pending
- 2014-03-14 US US14/774,685 patent/US9670209B2/en not_active Expired - Fee Related
- 2014-03-14 MX MX2015012043A patent/MX2015012043A/es unknown
- 2014-03-14 CN CN201480015640.8A patent/CN105120865A/zh active Pending
- 2014-03-14 KR KR1020157025205A patent/KR20150143439A/ko not_active Withdrawn
- 2014-03-14 CA CA2903276A patent/CA2903276A1/en not_active Abandoned
- 2014-03-14 TW TW103109294A patent/TW201446761A/zh unknown
- 2014-03-14 BR BR112015021271A patent/BR112015021271A2/pt not_active IP Right Cessation
- 2014-03-14 EP EP14715518.8A patent/EP2976079A1/en not_active Withdrawn
-
2015
- 2015-09-01 IL IL241001A patent/IL241001A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016513677A (ja) | 2016-05-16 |
| US9670209B2 (en) | 2017-06-06 |
| RU2015144155A (ru) | 2017-04-24 |
| EP2976079A1 (en) | 2016-01-27 |
| AU2014240139A1 (en) | 2015-09-17 |
| US20160039819A1 (en) | 2016-02-11 |
| CN105120865A (zh) | 2015-12-02 |
| IL241001A0 (en) | 2015-11-30 |
| WO2014152144A1 (en) | 2014-09-25 |
| KR20150143439A (ko) | 2015-12-23 |
| CA2903276A1 (en) | 2014-09-25 |
| BR112015021271A2 (pt) | 2017-08-22 |
| TW201446761A (zh) | 2014-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| IN2015DN01156A (enExample) | ||
| MX381417B (es) | Inhibidores de glucosidasa. | |
| IN2014DN06812A (enExample) | ||
| MX359327B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| IN2015DN00438A (enExample) | ||
| PH12015500433B1 (en) | Methods and compositions for treatment of a genetic condition | |
| TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
| PH12014501844B1 (en) | Peptidomimetic macrocycles | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| TW201144301A (en) | Processes for preparing linezolid | |
| MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| GEP20166489B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| MX2014011103A (es) | Moduladores del receptor x del higado. | |
| EA201491894A1 (ru) | Способы лечения непереносимости лактозы | |
| BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| MX2016003248A (es) | Metodos de uso de anticuerpos anti-lgr5. | |
| MX2015012043A (es) | Agonistas muscarinicos. | |
| EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| MX2015016167A (es) | Tratamiento de la vasculopatia coroidea polipoidal. |